Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors have evaluated a new kinetic acid phosphatase method in which the substrate is alpha-naphthyl phosphate. The original claim that this substrate was highly specific for the prostatic isozyme has been strongly challenged. Therefore, large numbers of patients in the following groupings were included in the evaluation: 52 urology clinic patients, 17 patients with uremia, 11 patients with multiple myeloma and 231 patients who had undergone prostatic biopsies. Two hundred seventy of these patients were found to be free of prostatic cancer. Of these, seven had acid phosphatase values above the upper limit of normal. Five of these seven patients had diagnoses of fibromuscular glandular hyperplasia. One was a woman who had multiple myeloma, and one was a uremic patient. Fifteen of 17 patients who had metastatic cancer of the prostate had elevated acid phosphatase activities, whereas one of 24 patients who had cancer of the prostate but no evidence of metastases had an elevated value.
 ...
PMID:An evaluation of a kinetic acid phosphatase method. 86 5

Total prostatectomy in the properly selected patient will provide disease-free survival rates comparable to the expected survival in similarly aged men for up to 30 years of observation (Figure 4). Patients who undergo total prostatectomy accept a very small risk of long-term permanent complications or mortality, and effective treatment is available for most complications. The morbidity and costs associated with hormone refractory metastatic prostate cancer are significant, with bone pain and anemia from bone marrow invasion, bladder dysfunction (retention, incontinence, and hematuria), urinary tract infection, anorexia, and uremia from obstructed ureters being common sequelae in the months before death. In the properly selected patient, minimal risk is incurred from total prostatectomy, the potential complications are well defined and manageable, and long-term disease-free survival is seen in most patients.
 ...
PMID:Localized prostate carcinoma. Surgical management. 822 51

To determine the clinical usefulness of the autopsy in elderly patients, we studied a total of 231 autopsies performed during 1986 and 1995 at Jikeikai hospital. Autopsies were done after 231 of 609 deaths (38%). The autopsy rate in our hospital fell from 63% in 1986 to 17% in 1995. Most primary causes of deaths as established by clinicians before autopsy were pulmonary, neoplastic, and cardiovascular diseases. The probability of a major unexpected finding at autopsy was higher in acute pneumonia, acute myocardial infarction, and cerebrovascular disease. No primary pathological cause of death was established by pathologists at autopsy in 13 cases (The clinical diagnoses in those patients were acute pneumonia in 5 patients, acute myocardial infarction in 2 patients, sepsis in 2 patients, bronchiale asthma, cerebral infarction, uremia, gastrointestinal bleeding each in 1 patient.) The mean age of these 13 patients was higher by 5 years than the age of the group as a whole. This indicate that elderly patients have many complications and that these deaths were caused by many small changes that were not be detected at autopsy. Latent cancer was found in 23 cases (12%): thyroid and colon cancer in 6 patients each, gastric cancer in 4, prostate cancer in 3, ovarian cancer in 2, and other cancers (renal, uterine, lung, urethral, pancreatis and liver) each 1 in patient.
 ...
PMID:[Clinical usefulness of the autopsy in elderly patients]. 1021 66

The most common form of hormonal treatment for prostate cancer is luteinizing hormone-releasing hormone (LHRH)-agonist therapy. During the first 1 to 3 weeks of LHRH-agonist therapy, an initial increase in testosterone is associated with a condition known as "flare." Blockade of flare can be accomplished with a number of agents, including flutamide, bicalutamide, nilutamide, diethylstilbestrol, ketoconazole, and cyproterone acetate. Evidence from the early use of LHRHagonists suggested that flare could be serious in nature, with an exacerbation of pain, increase in uremia, development of neurologic sequelae, and possibly death. These events have been uncommonly reported of late, most probably owing to the use of flare blockade in most patients with advanced disease, as well as the fact that many patients are currently being treated with much earlier disease. Evidence is conflicting as to whether flare makes a difference in less advanced disease. A few reports have noted complications during flare in patients in whom a blockade of flare was not required, including two deaths from one institution. Reported series, however, seem to suggest that with flare blockade, acute complications are extremely uncommon. Evidence suggests that 1) advanced disease should be blocked; 2) blockade should probably include an antiandrogen beginning about 1 week prior to administration of the LHRH-agonist; and 3) that patients without advanced disease but with very high PSA levels should be considered for flare blockade.
 ...
PMID:Flare Associated with LHRH-Agonist Therapy. 1698 3

The prostate-specific antigen (PSA), a glycoprotein, is a clinically used biomarker for screen and diagnosis of prostate cancer. Most of PSA in blood circulation is protein-bound, and only a small fraction is present as free PSA. In general, the serum total PSA levels are <4ng/mL in healthy controls and significantly increased in certain prostate cancer patients. Currently, <0.25 in the ratio of free PSA to total PSA (F/T value) is used as an indicator of prostate cancer. The mRNA of PSA is mainly expressed in prostate, and its protein product is a protease present in seminal plasma for the liquefaction of seminal coagulum in normal physiology. The F/T value as a prostate cancer biomarker has been questioned for its benefit over harm caused by its high false-positive rate of diagnosis. Furthermore, the molecular basis of how PSA is getting into blood circulation from seminal plasma is largely unknown. In current study, a total of 24,692 clinical lab test results of serum F/T values from healthy controls and patients with 34 different types of diseases including different types of cancers and nonneoplasm illnesses during the past 5 years were collected and analyzed statistically. Our data showed that even though the prostate cancer patients had the lowest median serum F/T values, both significantly increased and decreased serum F/T values were associated with different types of human diseases, such as acute cerebral infarction, coronary heart disease, uremia, and nephrotic syndrome. The possible molecular mechanisms of serum PSA as disease biomarkers are discussed.
 ...
PMID:Serum PSA levels in patients with prostate cancer and other 33 different types of diseases. 3090 64